Literature DB >> 21647535

Evaluation of the PC-1 K121Q and G2906C variants as independent risk factors for ischaemic stroke.

M Rieger1, G Endler, M Funk, W Lalouschek, W Lang, C Mannhalter, R Sunder-Plassmann.   

Abstract

UNLABELLED: Overexpression of plasma cell membrane glycoprotein-1 (PC-1) inhibits insulin receptor tyrosine kinase activity and thus favours insulin resistance and atherosclerotic vascular disease. Recent findings indicate that the minor variant K121Q in the PC-1 gene confers an increased risk for early myocardial infarction independent of other established risk factors. We hypothesized that genetic variants in PC-1 may also influence the risk for cerebrovascular disease. AIM: Therefore, we assessed the association of the PC-1 K121Q variant in the coding region and a polymorphism (G2906C) in the 3' untranslated region of the PC-1 gene with the risk of stroke. PATIENTS: We analyzed 1014 patients with a history of ischaemic stroke from the Vienna stroke registry and 1001 control individuals without vascular disease. RESULTS,
CONCLUSION: Genotype frequencies of both genetic variants were similar in patients and controls in the total study population. By multivariate analysis, no interactions were observed between the PC-1 genotype and established vascular risk factors. However, the PC-1 2906C allele was significantly more frequent in patients who suffered from stroke before the age of 40 years. In these patients the risk for ischaemic stroke was increased four-fold.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647535     DOI: 10.5482/ha-1142

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  1 in total

1.  Genetic determinants and early carotid atherosclerosis: is there a role for the ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP-1) K121Q polymorphism? Preliminary results in non diabetic individuals.

Authors:  P Coletta; G Barbarossa; D Pergolini; L D'Erasmo; A Renzi; L Mercuri; M G Anatra; E Ciociola; A Verrienti; M Maranghi
Journal:  Endocrine       Date:  2012-08-17       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.